TW201437298A - Virus inactivating agent - Google Patents

Abstract

The object of this invention is to provide a virus inactivating agent with high safety and low environmental burden, which can be widely used in the fields requiring virus inactivation, antibacterial and mildew-proof, upon healthy and hygiene aspects. The virus inactivating agent contains a PGA ionic complex formed from a poly- γ -glutamic acid and a cationic bactericidal agent.

Description

Virus inactivating agent

The present invention relates to virus inactivators which are applicable to various materials including plastics, films, fibers, wood, paper, cement, metals, ceramics, glass, and the like.

Viral infections are diseases that cause serious symptoms such as hepatitis, AIDS, madness, encephalitis, and cold symptoms, and are a permanent threat to humans. In recent years, influenza viruses have proliferated around the world, and from time to time, they have caused pandemics due to new influenza that exhibits antigenic changes. They not only affect life and health, but also affect economic activities and social functions, and become new threats to human beings. In addition to hoping to develop therapeutic drugs that are effective against viral infections as early as possible, it is also hoped that for the purpose of suppressing viral infection, the viruses, cosmetics, and sanitary products, etc., are not activated by the living supplies related to clothing, food, and clothing. In particular, caregivers and medical sites that increase with ageing are worried about nosocomial infections. They require not only antibacterial and anti-mildew, but also masks, towels, gauze, clothing, and other hygiene products that are not activated by the virus. Therefore, it is strongly hoped that development will be safe and effective. Virus inactivating agent.

In the past, for the purpose of virus inactivation, ethanol, sodium hypochlorite, and two were used. Chlorine oxide, glutaraldehyde, etc. However, these general disinfectants have only a one-time effect because of their high volatility and low persistence of virus inactivation. Furthermore, due to the high irritation to the mucous membrane and the skin, the use is limited in consideration of safety.

The virus inactivating agents other than the above are mainly classified into metals and non-metals. Metals have been known since ancient times as metal ions such as silver, copper, and zinc as antibacterial agents, particularly silver ions, which have high safety and are inactivated against viruses. For example, Patent Document 1 discloses a fabric in which silver ions are adhered to a fiber product containing an inorganic porous substance.

Examples of the non-metal virus inactivator include a quaternary ammonium salt and a composition derived from a natural product. A quaternary ammonium salt. For example, Patent Document 2 discloses an antiviral agent composition comprising octadecyldimethyl(3-triethoxycarbenylpropyl)ammonium chloride. A composition derived from a natural product, for example, Patent Documents 3 to 4, is a fiber product derived from a composition of a natural product such as catechin or polyphenol.

In the above Patent Document 1, since silver ions are dispersed in a fiber product, it is necessary to have a porous material such as zeolite or silicone rubber, and the use form is limited, and the moldability is limited. On the other hand, in the above Patent Document 2, octadecyldimethyl(3-triethoxymethanealkylpropyl)ammonium chloride has good adhesion to glass, fibers, and the like, and has high persistence of virus inactivation. . However, this ruthenium compound has a drawback that the surface of the resin having no oxy group or hydroxyl group is low in adhesion. Further, in the above Patent Documents 3 to 4, since the effective composition is necessary for extraction and purification from plants, there is a problem that a large amount of waste is generated and the environmental burden is large.

In view of this situation, it is expected that a material having high safety to the human body, strong adhesion to materials, and low environmental burden is considered as a virus inactivating agent.

In recent years, biopolymers derived from natural materials and biopolymers have attracted attention. The biopolymer is highly safe to the human body, and since it can be directly used as a material, it does not generate waste and has a small environmental burden. Further, it has an advantage of high biodegradability, and is expected to be used as a resource that does not depend on petrochemical materials. Biopolymers have progressed to the development of poly-gamma-glutamic acid (hereinafter sometimes referred to as PGA). Poly-γ-glutamic acid is a polyamino acid in which an α-amino group of glutamic acid is bonded to a γ-carboxyl group by a guanamine bond. PGA is known as a main component of natto-drawing, and its attractive function is that it has both biodegradability and adhesion.

Patent Document 6 describes an ion complex (hereinafter sometimes referred to as PGAIC) composed of a poly-γ-glutamic acid and a quaternary ammonium ion compound. The ionic composite is an insoluble polymer and is expected to have new uses. This document describes the usefulness of a film formed from the ionic composite as a material having bacteriostatic properties. However, the effect of inactivation of the virus is unknown.

[Previous Technical Literature]

[Patent Literature]

[Patent Document 1] Japanese Patent Laid-Open Publication No. 2008-188791

[Patent Document 2] Japanese Patent Laid-Open Publication No. 2011-98976

[Patent Document 3] Japanese Patent Laid-Open Publication No. 2009-17323

[Patent Document 4] Japanese Patent Laid-Open Publication No. 2006-21095

[Patent Document 5] Japanese Patent Laid-Open Publication No. 2012-25698

[Patent Document 6] Japanese Patent Laid-Open Publication No. 2010-222496

As described above, it is desirable to have high safety to the human body, strong material adhesion, low environmental burden, and can be applied to materials, and can be processed into various forms such as films, plastics, fibers, liquids, and colloids. Activator.

An object of the present invention is to provide a virus inactivating agent which can be used in a wide range of fields where antiviral properties are required for health and hygiene in order to provide an excellent inactivation effect on viruses.

The inventors of the present invention have conducted intensive studies to solve the above problems, and have found that an ion complex of poly-γ-glutamic acid has excellent characteristics as a virus inactivating agent, and completed the present invention. Namely, it has been found that an ionic complex formed of poly-γ-glutamic acid and a cationic bactericide, particularly a quaternary ammonium salt or a biguanide bactericide, exhibits virus inactivation, and the present invention has been completed.

The present invention provides a virus inactivating agent comprising a poly-γ-glutamic acid ion complex with high safety and low environmental burden.

Representative inventions are as follows.

(item 1)

A virus inactivating agent comprising a PGA ion complex formed by poly-γ-glutamic acid and a cationic bactericide.

(item 2)

The virus inactivating agent according to Item 1, wherein the cationic bactericide is a quaternary ammonium salt.

(item 3)

The virus inactivating agent according to Item 1, wherein the cationic bactericide is a biguanide bactericide.

(item 4)

The virus inactivating agent according to Item 1, wherein the cationic bactericide is selected from the group consisting of cetylpyridinium chloride, bensonin chloride, chlorhexidine hydrochloride and chlorhexidine gluconate. More than one.

(item 5)

The virus inactivating agent according to any one of items 1 to 4, wherein the proportion of L-glutamic acid in the glutamic acid constituting the poly-γ-glutamic acid is 90% or more.

(Item 6)

The virus inactivating agent according to Item 5, wherein the glutamic acid constituting the poly-γ-glutamic acid is composed of L-glutamic acid.

(item 7)

A polymer resin composition which is a virus inactivating agent according to any one of Items 1 to 6.

(item 8)

A paint comprising the virus inactivator according to any one of items 1 to 6.

(item 9)

A spray agent comprising the virus inactivator according to any one of items 1 to 6.

The present invention has excellent characteristics as a virus inactivating agent, and is insoluble in an ion complex formed of poly-γ-glutamic acid and a cationic bactericide, and has high residual property, and is displayed for a long time even when used at a low concentration. Antiviral effect, virus inactivation effect. Furthermore, the present invention can be applied to various materials including plastics, films, fibers, wood, paper, cement, metals, ceramics, glass, etc., and can be applied to various forms such as films, plastics, fibers, liquids, gels, and the like. The point is also excellent. Further, in addition to the biodegradability of the poly-γ-glutamic acid itself, the quaternary ammonium salt or the biguanide fungicide which is paired with a cation can also be used as a surfactant or a bactericide, and thus has high safety. Therefore, the present invention can provide a virus inactivating agent which can exhibit an excellent non-activation effect on a virus and can be utilized in a wide range of fields where antiviral properties are required in terms of health and hygiene.

The present invention provides a virus inactivating agent containing an ionic complex (hereinafter abbreviated as PGA ion complex) formed of poly-γ-glutamic acid and a cationic bactericide.

Poly-γ-glutamic acid (hereinafter abbreviated as PGA) is a polyamino acid in which an α-amino group of glutamic acid is combined with a γ-carboxyl group. The type of the PGA is not particularly limited. For example, those composed only of L-glutamic acid, those consisting only of D-glutamic acid, or both may be used. However, when the ratio of one of the components is large, the stereoregularity is excellent, and the strength and the like are also high. Further, if it is sufficiently dried, a melting point (150 ° C) is also exhibited. This melting point is more clearly defined as an ion complex. Further, since one of the components of L-glutamic acid is excellent in biodegradability, it is preferred to use a PGA having a content ratio of L-glutamic acid of 90% or more.

The molecular size of the PGA to be used is also not particularly limited, but it is preferably an average molecular mass of 10 kD or more. Generally, the larger the molecular size, the higher the strength and the like. On the other hand, the cost of manufacturing a PGA having an excessively large molecular size is increased, and further, manufacturing techniques are often difficult, and therefore, it is usually set to be 1,000 kD or less.

You can use the PGA of the market and you can make it separately. However, under ordinary conditions, by polymerizing L-glutamic acid to obtain poly-α-glutamic acid, it is preferred to use a microorganism for biosynthesis . The microorganisms producing PGA include Bacillus subtilis , Bacillus subtillis , Bacillus megaterium , Bacillus anthracis , Bacillus halodurans , Natrialba aegyptiaca , Hydra, and the like. The microorganism capable of producing macromolecular PGA is Bacillus subtillis and the hyper-halophilic archaea Natrialba a egyptiaca . Among them, PGA is preferably produced by the microorganism Natrialba aegyptiaca which produces only PGA consisting of L-glutamic acid.

The cationic bactericide contained in the ionic composite of the present invention is not particularly limited, but is preferably a quaternary ammonium salt or a biguanide bactericide. The quaternary ammonium salt is, for example, cetylpyridinium chloride, benzethonium chloride, distearyldimethylammonium chloride, stearyl dimethyl chloride Stearyl dimethyl benzyl ammonium chloride, stearyl trimethyl ammonium chloride, cetyl trimethyl ammonium chloride, lauryl chloride Lauryl trimethyl ammonium chloride, lauryl pyridinium chloride, and the like. Biguanide fungicides such as chlorhexidine, chlorhexidine acetate, chlorhexidine gluconate, alexidine hydrochloric acid, acetic acid acetate Acid alexidine), gluconate, alexidine. Among them, cetylpyridinium chloride, bensinin chloride, chlorhexidine hydrochloride, and chlorhexidine gluconate are preferred. The ionic complex may be formed only by one of the positive bactericidal agents, or may be composed of two or more kinds of PGA ion complexes.

In the PGA ion composite according to the present invention, a glutamic acid and a cationic bactericide which constitute a PGA including an equimolar ratio or an arbitrary molar ratio may be used, but in order to overcome the disadvantage of excessive hydrophilicity of a material having PGA, it is preferred. For The cationic bactericide is fully modified. More specifically, in the PGA ion composite, the ratio of the cationic bactericide is preferably 0.5 mol or more, more preferably 0.6 mol or more, or more preferably, relative to the glutamic acid constituting the PGA. 0.7 more than double. In particular, it is preferably a glutamic acid and a cationic bactericide which constitute a PGA, such as a molar or an approximate molar. Here, the approximate moir means that the moiré numbers of the two are almost equal, and specifically, it means that the cationic bactericide is 0.8 mol or more and 1.2 mol times or less with respect to the glutamic acid constituting the PGA. In particular, it is 0.9 Mol or more and 1.1 Molbe or less.

The PGA ion complex of the present invention can be produced by mixing a PGA with a cationic bactericide such as a quaternary ammonium salt or a biguanide bactericide in a solvent.

The solvent used herein is preferably water. Since the PGA raw material can be well dissolved, the PGA ion complex of the target compound is insoluble to water, so it is convenient to separate and purify the target after the reaction. However, the solubility of the cationic bactericide is high, and the solubility in the reaction liquid is high. An alcohol such as methanol or ethanol, an ether such as THF, or a guanamine such as dimethylformamide or dimethylacetamide may be used. A water-soluble organic solvent is added to the reaction liquid. However, in consideration of the completion of the reaction, the PGA ion complex must be separated, and it is preferred to use only water as a solvent.

As the raw material PGA, a salt thereof can also be used. These salts are, for example, an alkali metal salt such as a sodium salt or a potassium salt, an alkaline earth metal salt such as a calcium salt or a magnesium salt, or the like. Again, even if it is In the case of using a salt, it is not necessary to change all the carboxyl groups into a salt, and only a part of them may become a salt. However, in the case where the polyvalent metal salt such as an alkaline earth metal salt has low solubility in water, it is preferred to use a free state of PGA or a monovalent metal salt of PGA.

A quaternary ammonium salt or a biguanide fungicide, usually in the form of a halogenated salt. Therefore, in the present invention, a quaternary ammonium salt or a biguanide bactericide may be directly added to the reaction liquid, or the salt may be added after being dissolved in an aqueous solvent. For the quaternary ammonium salt or biguanide fungicide, in order to fully modify the PGA, it is preferred to use a sufficient amount for the PGA.

Since the PGA ion complex of the present invention is insoluble in water, it is easily separated from the aqueous solvent, and the concentration of each component in the reaction liquid is not particularly limited. For example, the concentration of PGA in the reaction liquid may be 0.5 w/v% or more, 10 w/v% or less, and the concentration of the cationic bactericide is 1.0 w/v% or more and 10 w/v% or less.

In order to promote the formation of the composite, it is preferred to appropriately heat the reaction liquid. The heating temperature can be, for example, 40 ° C or higher and 80 ° C or lower. The reaction time may be appropriately adjusted, and is usually 1 hour or more and 20 hours or less.

Since the PGA ion complex of the present invention is insoluble in water, it can be easily separated from the aqueous solvent by filtration or centrifugation. Furthermore, the separated PGA ion complex is washed with water, and may also remove excess PGA or cations. Bacterial agents, other salts. Further, the aqueous solvent can be easily removed by washing with acetone.

The PGA ion complex of the present invention exhibits biodegradability and has moisture retention without exhibiting water solubility and excessive water absorption. In addition, there is a clear melting point, and the melting point is sufficiently isolated from the thermal decomposition starting point, so it can be heated and molded.

The PGA ion complex of the present invention can be utilized as a virus inactivating agent which is widely used in the field of requiring antiviral health and hygiene.

The PGA ion complex of the present invention contains a quaternary ammonium salt or a biguanide site, which can destroy the lipid bilayer membrane of the capsular virus and is not activated. Capsular viruses such as influenza A virus, influenza B virus, novel influenza virus, parainfluenza virus, herpes virus, mumps virus, Newcastle disease virus, measles virus, RS virus, rabies virus, coronavirus, Buni A virus that retains a capsule such as a subvirus, a human T lymphoblastic virus, or an HIV virus. Among them, it is preferred that the influenza A virus, the influenza B virus, and the novel influenza virus are not activated.

The PGA ion complex of the present invention is used as a virus inactivating agent, for example, in combination with a polymer resin composition, a coating material, a spray, and the like. The PGA ion composite is a biodegradable polymer and has high safety, so it can be used as a virus inactivating agent with a low environmental burden. Furthermore, PGA Ionic composites have adhesive properties and are insoluble in water, especially in the use of coatings and sprays, and are available as persistent viral inactivating agents.

When the virus inactivating agent of the present invention is used as a composition of the antiviral polymer resin, the type of the polymer resin is not particularly limited, and can be freely selected for use of the resin composition or the like. Specific examples of the resin to be used include, for example, a vinyl chloride polymer, a urethane polymer, an acrylic polymer, an olefin polymer, a vinyl polymer, a propylene polymer, and a guanamine polymer. Ethylene vinyl acetate copolymer, vinylidene chloride polymer, styrene polymer, ester polymer, nylon polymer, cellulose derivative, carbonate polymer, fluorine resin, antimony system Resin, vinyl alcohol polymer, vinyl ester polymer, synthetic rubber, natural rubber, and the like. The resin composition may be appropriately blended with a plasticizer, a filler, a colorant (dye, pigment, etc.), an ultraviolet absorber, or the like, as necessary. The compounding ratio is preferably within a range which can exhibit a virus inactivation effect without impairing the function of the polymer resin. Specifically, it is preferably 0.1 to 5.0%. More preferably, it is 0.1% to 2.0%.

The above resin composition can be processed into various forms for its use and the like. For example, the composition of the present invention can be formed into a film shape, a sheet shape, a plate shape, a fiber shape, or a three-dimensional shape by a resin processing method known per se, such as extrusion molding, injection molding, solution casting, or spinning. For example, it can be utilized for interior materials, bedding materials, fiber products, home electric appliances, and the like.

When the virus inactivation treatment is applied to the industrial product or the substrate by using the virus inactivating agent of the present invention, it can be treated by a method such as brushing, spraying, dipping, coating, or printing, and is not particularly limited.

The virus inactivating agent of the present invention can be dissolved or dispersed in a solvent for coating, and an appropriate pigment, a crosslinking agent and other additives for coating can be blended to form an antiviral coating. In this case, the base material of the coating material may, for example, be ceramic, metal, metal oxide, plastic, rubber, ore, wood or the like. Specifically, examples of the ceramics include glass, ceramics, cement, refractory bricks, enamel, and the like. Examples of the metal include metal monomers such as iron, aluminum, zinc, magnesium, gold, silver, chromium, lanthanum, molybdenum, nickel, lead, platinum, rhodium, titanium, ruthenium, tungsten, or carbon steel, nickel steel, Alloys such as chrome steel, chrome molybdenum steel, stainless steel, aluminum alloy, brass, bronze. Examples of the metal oxide include alumina, cerium oxide, magnesium oxide, cerium oxide, zirconium oxide, ferric oxide, triiron tetroxide, titanium oxide, calcium oxide, zinc oxide, and lead oxide. Examples of plastics include general-purpose plastics such as polyvinyl chloride, polyethylene, polypropylene, polystyrene, polyethylene terephthalate, and polyvinyl alcohol; polyamine, polycarbonate, polyoxymethylene, and polyfluoride. Engineering plastics such as vinylidene, polyether oxime, polyamido-quinone imine; thermosetting resins such as phenolic resin, epoxy resin, enamel resin, and polyurethane. Examples of ores include marble and granite. The solvent for coating contains preferably 0.1% or more, more preferably 0.5% or more of the virus inactivating agent. If it is less than 0.1%, the virus inactivation effect may not be fully exerted. Moreover, in order to use as a coating material, it is preferable that it is 20 % or less.

Further, the virus inactivating agent of the present invention can be used as an antiviral spray. Specifically, the virus can be inactivated by direct spray coating of a bathroom, a sink, a sanitary machine, or the like in a home, a hospital, a public facility, or the like. In this case, the dispersion used in the nebulizer is preferably water; alcohol such as ethanol, methanol or isopropanol; and a solvent of a hydrocarbon such as n-hexane, and a ketone or ester can also be used from the viewpoint of safety. Various solvents such as fatty acids and eucalyptus oils. These solvents may be used alone or in combination of two or more. The spray agent preferably contains 0.1% or more, more preferably 0.5% or more of the virus inactivating agent. If it is less than 0.1%, the virus inactivation effect may not be fully exerted. Although the upper limit is not particularly limited, when it is dissolved in a solvent, the virus inactivating agent is preferably 20% or less.

Alternatively, the inner surface of the metal mold of the plastic injection molding machine can be spray-coated to indirectly transfer the anti-viral property of the molded plastic surface, and the virus on the wall surface or the plastic surface can be inactivated for a long time.

One aspect of the virus inactivating agent of the present invention is that the PGA ion complex has a clear melting point and the melting point is sufficiently separated from the thermal decomposition starting point, so it is possible to use this property to heat form as a bioplastic. The material can be processed into a film-shaped molded body or the like.

Another aspect of the virus inactivating agent of the present invention is a solution spinning method of a PGA ion composite by a wet spinning method, a dry-wet spinning method, a dry spinning method, a gel spinning method, or the like. Spinning spinning, electrospinning, etc. The silk can be used as a fiber structure such as a woven fabric or a non-woven fabric. For example, it is dissolved in an alcohol-based solvent such as methanol or ethanol, or an ether-based solvent such as diethyl ether or tetrahydrofuran, and is electrospun (the charged polymer solution is ejected from the tip of the nozzle in an electric field, and the charge repulsive force of the solution is finely obtained. Method for producing a fibrous material) A nanofiber can be produced into a non-woven fibrous structure.

[Examples]

The present invention will be described in more detail by the following examples, but these examples are not intended to limit the invention.

(Example 1) Production of PGAIC100 (PGA/CPC)

A poly-γ-L-valine sodium salt (40 g) derived from a super-halophilic archaea Natrialba aegyptiaca ( N. aegyptiaca ) having an average molecular weight of 1000 kD was dissolved in purified water to prepare a 0.2 w/v% solution. To the solution was added a 0.2 M aqueous solution (1551 g) of cetylpyridinium chloride (CPC) incubated at 60 °C. From the aqueous solution of the raw material poly-γ-L-valine sodium salt (content: 90% or more), it was confirmed that a water-insoluble material was formed immediately after the addition of CPC, and then the temperature was kept at 60 ° C for 4 hours. After the obtained water-insoluble material was collected by filtration, it was washed three times with 1000 mL of purified water. After dehydration by acetone washing, it was dried under vacuum to recover an ion complex powder (93 g). From the results of ¹ H-NMR of the obtained ion complex, it was confirmed that L-PGA and CPC were combined at a molar ratio of 100:100.

(Example 2) Production of PGAIC (L-PGA/CPC) coated film

The ionic complex (20 g) obtained in Example 1 was dissolved in 99.5% ethanol to prepare a 20 wt% solution. The obtained ethanol solution was applied onto a PET film having a thickness of 188 μm by an applicator, and the solvent was dried to prepare a PGAIC coating film having a coating film thickness of 18 μm.

(Example 3) Virus inactivation test of PGAIC (L-PGA/CPC) coated film

According to the antibacterial test method JIS Z2801, the PGAIC (L-PGA/CPC)-coated film prepared in Example 2 was cut into a square having a side length of 50 mm, placed in a petri dish, and 0.2 mL of the virus solution was dropped, and the solution was contacted at 25 °C. After 24 hours, 10 mL of phosphate buffered saline was added to recover the liquid in the culture dish. The virus system uses influenza A virus and influenza B virus. The viral infection price was calculated by the Reed-Muench method (Reed, LJ & Muench, H. (1938) Am. J. Hygiene, 27, 493-497). Further, the same operation was carried out using an untreated PET film as a control group. The antibacterial effect of the PGAIC-coated film was determined by the log ₁₀ (infection price of the untreated PET film/infection price of the PGAIC-coated film) with respect to the reduction of the untreated PET film after 24 hours of action.

The results are shown in Table 1. The result was: for influenza A virus, the viral infection price of the PGAIC-coated membrane was 1.7 x 10 TCID ₅₀ /mL, and the antiviral effect was 5.4. Furthermore, for the influenza B virus, the viral infection price of the PGAIC-coated film is a detection limit of 1.3×10 ² TCID ₅₀ /mL or less, and the antiviral effect is 3.2 or more. An anti-virus effect of 2.0 or more was judged as "valid". From the above results, it was confirmed that the PGAIC (L-PGA/CPC) coated film has no activation effect on the influenza A virus and the influenza B virus.

[Industrial availability]

The virus inactivating agent of the present invention can be used in a wide range of fields requiring antibacterial and antifungal properties and virus inactivation in terms of health and hygiene in the form of a resin composition, a paint, a spray, and the like.

Claims (9)

A virus inactivating agent comprising a PGA ion complex formed by poly-γ-glutamic acid and a cationic bactericide. The virus inactivating agent according to claim 1, wherein the cationic bactericide is a quaternary ammonium salt. The virus inactivating agent according to claim 1, wherein the cationic bactericide is a biguanide bactericide. The virus inactivating agent according to claim 1, wherein the cationic bactericide is selected from the group consisting of cetylpyridinium chloride, bensonin chloride, chlorhexidine hydrochloride and chlorhexidine gluconate. More than one. The virus inactivating agent according to any one of claims 1 to 4, wherein a proportion of L-glutamic acid in the glutamic acid constituting the poly-γ-glutamic acid is 90% or more. The virus inactivating agent according to claim 5, wherein the glutamic acid constituting the poly-γ-glutamic acid is composed of L-glutamic acid. A polymer resin composition which is a virus inactivating agent according to any one of claims 1 to 6. A coating material containing the virus inactivating agent according to any one of claims 1 to 6. A spray containing the virus according to any one of claims 1 to 6. Not activator.